Our pipeline

We have an exciting and balanced pipeline underpinned by great science.

Latest quarterly updates

Our pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development.


143

projects in our pipeline

9

new molecular entities in our late-stage pipeline


Phase III/Reg.* refers to assets that are in Phase III or that have been submitted for regulatory approval, and may include assets that are now launched in one or more major markets.

Filter By:

Oncology (as at 26 July 2018)

Phase 1

Phase 1

  • AZD0156 solid tumours
  • AZD1390 glioblastoma
  • AZD4573 haematalogical malignancies
  • AZD4635 solid tumours
  • AZD4785 solid tumours
  • AZD5153 solid tumours
  • AZD5991 haematalogical malignancies
  • AZD9496 oestrogen receptor +ve breast cancer
  • Calquence + AZD6738 haematological malignancies
  • Calquence + vistusertib haematalogical malignancies
  • Imfinzi + Iressa non-small cell lung cancer
  • Imfinzi + MEDI0562 solid tumours
  • Imfinzi + MEDI9197 solid tumours
  • Imfinzi + adavosertib solid tumours
  • Imfinzi + dabrafenib + trametinib melanoma
  • Imfinzi + monalizumab solid tumours
  • Imfinzi + oleclumab solid tumours
  • Imfinzi + selumetinib solid tumours
  • Imfinzi + tremelimumab solid tumours
  • Imfinzi + tremelimumab + chemotherapy 1st-line pancreatic ductal adenocarcinoma, oesophageal and small cell lung cancer
  • Imfinzi or Imfinzi + (tremelimumab or danvatirsen) diffuse large B-cell lymphoma
  • Imfinzi + RT (platform) CLOVER locally-advanced head and neck squamous cell carcinoma, non-small cell lung cancer, small-cell lung cancer
  • Imfinzi + azacitidine myelodysplastic syndrome
  • Lynparza + adavosertib solid tumours
  • MEDI0562 solid tumours
  • MEDI1873 solid tumours
  • MEDI2228 multiple myeloma
  • MEDI3726 prostate cancer
  • MEDI5083 solid tumours
  • MEDI5752 solid tumours
  • MEDI7247 haematological malignancies
  • MEDI9197 solid tumours
  • oleclumab solid tumours
  • oleclumab + AZD4635 EGFRm NSCLC
  • tremelimumab + MEDI0562 solid tumours

Phase 2

Phase 2

  • AZD2811 solid tumours
  • AZD4547 solid tumours
  • AZD6738 solid tumours
  • AZD8186 solid tumours
  • Imfinzi solid tumours
  • Imfinzi + AZD5069 or Imfinzi + danvatirsen head and neck squamous cell carcinoma
  • Imfinzi + MEDI0680 solid tumours
  • Imfinzi + tremelimumab biliary tract, oesophageal
  • Imfinzi + tremelimumab gastric cancer
  • Imfinzi + Lynparza BAYOU 1st-line unresectable stage IV bladder cancer
  • Imfinzi + MEDI0457 head and neck squamous cell carcinoma
  • Lynparza + AZD6738 gastric cancer
  • Lynparza + Imfinzi MEDIOLA solid tumours
  • Tagrisso + or selumetinib or savolitinib) TATTON advanced EGFRm non-small cell lung cancer
  • adavosertib + chemotherapy ovarian cancer
  • capivasertib breast cancer
  • vistusertib solid tumours

Phase 3

Phase 3

  • Calquence B-cell malignancy
  • Imfinzi + tremelimumab DANUBE 1st-line bladder cancer
  • Imfinzi + tremelimumab EAGLE 2nd-line head and neck squamous cell carcinoma
  • Imfinzi + tremelimumab HIMALAYA 1st-line hepatocellular carcinoma
  • Imfinzi + tremelimumab KESTREL 1st-line head and neck squamous cell carcinoma
  • Imfinzi + tremelimumab MYSTIC 1st-line non-small cell lung cancer
  • Imfinzi + tremelimumab NEPTUNE 1st-line non-small cell lung cancer
  • Imfinzi + tremelimumab + SoC CASPIAN 1st-line small cell lung cancer
  • Imfinzi + tremelimumab + chemo POSEIDON 1st-line non-small cell lung cancer
  • Lynparza + cediranib CONCERTO recurrent platinum-resistant ovarian cancer
  • moxetumomab pasudotox PLAIT 3rd-line hairy cell leukaemia
  • savolitinib SAVOIR papillary renal cell carcinoma
  • selumetinib SPRINT paediatric neurofibromatosis type-1

LCM Projects

LCM Projects

  • Calquence 1st-line chronic lymphocytic leukaemia
  • Calquence relapsed/refractory chronic lymphocytic leukaemia
  • Calquence relapsed/refractory chronic lymphocytic leukaemia, high risk
  • Calquence B-cell malignancy
  • Calquence 1st-line mantle cell lymphoma
  • Imfinzi PACIFIC locally advanced (stage III) NSCLC
  • Imfinzi PEARL (China) 1st-line non-small cell lung cancer
  • Imfinzi + CRT PACIFIC-2 locally-advanced (stage III) NSCLC
  • Lynparza PROfound prostate cancer
  • Lynparza SOLO-1 1st-line BRCAm ovarian cancer
  • Lynparza SOLO-2 2nd-line or greater BRCAm PSR ovarian cancer, maintenance monotherapy
  • Lynparza OlympiA gBRCA adjuvant breast cancer
  • Lynparza OlympiAD gBRCA metastatic breast cancer
  • Lynparza POLO pancreatic cancer
  • Lynparza SOLO-3 gBRCA PSR ovarian cancer
  • Tagrisso ADAURA adjuvant EGFRm non-small cell lung cancer
  • Tagrisso FLAURA 1st-line advanced EGFRm non-small cell lung cancer

Cardiovascular and Metabolic Diseases (as at 26 July 2018)

Phase 1

Phase 1

  • AZD4831 heart failure with a preserved ejection fraction
  • AZD9977 CV disease
  • MEDI7219 type-2 diabetes

Phase 2

Phase 2

  • AZD5718 coronary artery disease
  • AZD8601 cardiovascular
  • MEDI0382 type-2 diabetes/obesity
  • MEDI5884 cardiovascular
  • MEDI6012 cardiovascular
  • verinurad chronic kidney disease

Phase 3

Phase 3

  • Epanova severe hypertriglyceridaemia
  • Lokelma hyperkalaemia
  • roxadustat anaemia in myelodysplastic syndrome
  • roxadustat OLYMPUS ROCKIES anaemia in chronic kidney disease/end-stage renal disease

LCM Projects

LCM Projects

  • Brilinta/Brilique THALES acute ischaemic stroke or transient ischaemic attack
  • Brilinta/Brilique HESTIA prevention of vaso-occlusive crises in paediatric patients with sickle cell disease
  • Brilinta/Brilique THEMIS cardiovascular outcomes trial in patients with type-2 diabetes and coronary artery disease without a previous history of myocardial infarction or stroke
  • Bydureon EXSCEL type-2 diabetes outcomes study
  • Bydureon Bcise (autoinjector) type-2 diabetes
  • Epanova STRENGTH cardiovascular outcomes study in statin-treated patients at high cardiovascular risk, with persistent hypertriglyceridemia plus low HDL-cholesterol
  • Farxiga/Forxiga worsening heart failure or cardiovascular death in patients with chronic heart failure
  • Farxiga/Forxiga renal outcomes and cardiovascular mortality in patients with chronic kidney disease
  • Farxiga/Forxiga type-1 diabetes
  • Farxiga/Forxiga DECLARE- TIMI 58 cardiovascular outcomes trial in patients with type-2 diabetes
  • Qtern type-2 diabetes
  • Xigduo XR/Xigduo type-2 diabetes
  • saxagliptin/dapagliflozin metformin type-2 diabetes

Respiratory (as at 26 July 2018)

Phase 1

Phase 1

  • AZD1402 asthma
  • AZD5634 cystic fibrosis
  • AZD7594 + abediterol asthma/chronic obstructive pulmonary disease
  • MEDI3506 chronic obstructive pulmonary disease

Phase 2

Phase 2

  • AZD1419 asthma
  • AZD7594 asthma/chronic obstructive pulmonary disease
  • AZD7986 chronic obstructive pulmonary disease
  • AZD8871 chronic obstructive pulmonary disease
  • AZD9567 rheumatoid arthritis/respiratory
  • PT010 asthma
  • abediterol asthma/chronic obstructive pulmonary disease
  • tezepelumab atopic dermatitis

Phase 3

Phase 3

  • Bevespi Aerosphere PINNACLE chronic obstructive pulmonary disease
  • Fasenra CALIMA SIROCCO ZONDA BISE BORA GREGALE severe uncontrolled asthma
  • PT010 chronic obstructive pulmonary disease
  • tezepelumab NAVIGATOR SOURCE severe, uncontrolled asthma

LCM Projects

LCM Projects

  • Duaklir Genuair chronic obstructive pulmonary disease
  • Fasenra OSTRO nasal polyposis
  • Fasenra TERRANOVA GALATHEA chronic obstructive pulmonary disease
  • Symbicort SYGMA as-needed use in mild asthma

Other (as at 26 July 2018)

Phase 1

Phase 1

  • AZD0284 psoriasis/respiratory
  • MEDI0700 systemic lupus erythematosus
  • MEDI1341 parkinson's disease
  • MEDI1814 Alzheimer’s disease
  • MEDI7352 osteoarthritis pain

Phase 2

Phase 2

  • MEDI3902 prevention of nosocomial Pseudomonas aeruginosa pneumonia
  • MEDI8852 influenza A treatment
  • MEDI8897 passive RSV prophylaxis
  • anifrolumab lupus nephritis
  • anifrolumab systemic lupus erythematosus (subcutaneous)
  • prezalumab primary Sjögren’s syndrome
  • suvratoxumab prevention of nosocomial Staphylococcus aureus pneumonia

Phase 3

Phase 3

  • anifrolumab TULIP systemic lupus erythematosus

LCM Projects

LCM Projects

  • Nexium stress ulcer prophylaxis
  • linaclotide irritable bowel syndrome with constipation (IBS-C)

Terminations